Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: A randomised, controlled, open-label trial
Background: In critically ill patients, antibiotic therapy is of great importance but long duration of treatment is associated with the development of antimicrobial resistance. Procalcitonin is a marker used to guide antibacterial therapy and reduce its duration, but data about safety of this reduction are scarce. We assessed the efficacy and safety of procalcitonin-guided antibiotic treatment in patients in intensive care units (ICUs) in a health-care system with a comparatively low use of antibiotics. Methods: We did a prospective, multicentre, randomised, controlled, open-label intervention... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2016 |
Schlagwörter: | NCT01139489 / antibiotic agent / C reactive protein / procalcitonin / adult / antibiotic therapy / article / clinical protocol / controlled study / critically ill patient / disease severity / drug efficacy / drug safety / female / human / immunoassay analyzer / infection / intensive care unit / major clinical study / male / mortality / multicenter study / Netherlands / open study / outcome assessment / practice guideline / priority journal / prospective study / randomized controlled trial / sepsis / septic shock / treatment duration / treatment outcome / Taverne |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-27220035 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://dspace.library.uu.nl/handle/1874/336993 |